Pharmaceutical Analytical Chemistry: Open Access
Open Access
ISSN: 2471-2698
ISSN: 2471-2698
Commentary - (2021)Volume 6, Issue 5
Proteomics is a relatively recent field; the term was coined in 1994 while science itself has its origins in the techniques of electrophoresis in the 1970s and 1980s. Protein research, however, has been the focus of science for a very long time. The study of proteins produces an understanding of how they affect cell processes. In contrast, this study also investigates how proteins themselves are affected by cell processes or the external environment. Proteins provide complex control of cellular machinery; in many cases, they are parts of the same machine. They perform various functions within a cell; there are thousands of different proteins and peptides in almost every living thing. The goal of proteomics is to analyze different proteomes of living things at different times in order to highlight the differences between them. Simply put, proteomics analyzes the structure and function of biological systems. For example, the proteins in a cancer cell are usually different from those of a healthy cell. Certain proteins in a cancerous cell may not be present in a healthy cell, making these unique proteins a good target for anti-cancer drugs. Achieving this goal is difficult; both the purification and identification of proteins in any organism can be prevented by biodiversity.
Cooximetry; Densitometry; Turbidimetry
The study of proteome activity is called proteomics. The proteome is the whole set of proteins produced by the cell type. Genomics has led to proteomics (with transcriptomics) as a logical step. Proteomes can be studied using genetic information because the genetic code for mRNAs and mRNAs binds to proteins. Proteomics is closely related to genomics and is useful when scientists want to test their genetic-based theories. Even though all the cells of a multicellular organism have the same set of genes, the set of proteins produced in different tissues is different and depends on gene expression. Thus, the genome does not change, but the proteome is flexible and dynamic within the organism. In addition, RNAs can be differentiated (cut and attached to form novel and protein compounds) and most proteins are converted after translation by processes such as proteolytic cleavage, phosphorylation, glycosylation, and the whole. There is also a protein-protein interaction, which makes it difficult for proteome research. Although the genome provides a blueprint, the final structure depends on a few factors that can change the continuation of proteome-producing events.
The genomes and proteomes of patients with certain diseases are being studied to understand the genetic basis of the disease. An outstanding set of diseases studied by proteomic cancer techniques. Proteomic methods are used to improve the diagnosis and early detection of cancer, which is achieved by identifying proteins whose expression is affected by the disease process.
Each protein that indicates disease is called a biomarker, and a set of proteins with modified speech levels is called a protein signature. For a biomarker or protein signature to be useful as a precautionary measure for early detection and cancer detection, it should be produced in body fluids (eg sweat, blood, or urine) so that large tests can be performed without invasive fashion. The current problem with using biomarkers for cancer detection is a high rate of untrue side effects. Fanga-negative is the result of a negative test that you should have said you had. In other words, many cancer cases are undetectable, making biomarkers unreliable. Other examples of protein biomarkers used in cancer detection are CA-125 for cervical cancer and PSA for prostate cancer. Protein signatures may be more reliable than biomarkers to detect cancer cells.
Proteomics is a work study of all the proteins shown. Significant progress has been made in the last few years in producing large data sets of protein and protein interactions, organelle formation, protein activity patterns and protein profiles in cancer patients. But further technological advances, international proteomics project planning and open access to results are needed for proteomics to realize its potential.
We have no conflict of interests to disclose and the manuscript has been read and approved by all named authors.
The Authors are very thankful and honored to publish this article in the respective Journal and are also very great full to the reviewers for their positive response to this article publication.
Received: 15-Oct-2021 Accepted: 29-Oct-2021 Published: 05-Nov-2021
Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.